Longboard Pharmaceuticals, Inc. LBPH
We take great care to ensure that the data presented and summarized in this overview for Longboard Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LBPH
View all-
Farallon Capital Management LLC San Francisco, CA3.15MShares$189 Million0.53% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.91MShares$174 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA2.79MShares$167 Million6.52% of portfolio
-
Black Rock Inc. New York, NY2.37MShares$142 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$122 Million0.0% of portfolio
-
Viking Global Investors LP1.97MShares$118 Million0.25% of portfolio
-
Wellington Management Group LLP Boston, MA1.59MShares$95.4 Million0.01% of portfolio
-
Polar Capital Holdings PLC London, X01.1MShares$66.1 Million0.23% of portfolio
-
Integral Health Asset Management, LLC1.05MShares$63 Million4.12% of portfolio
-
Goldman Sachs Group Inc New York, NY1.03MShares$61.6 Million0.01% of portfolio
Latest Institutional Activity in LBPH
Top Purchases
Top Sells
About LBPH
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Insider Transactions at LBPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,554
-100.0%
|
$1,833,240
$60.0 P/Share
|
|
Dec 02
2024
|
Kevin Robert Lind President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
363,740
-100.0%
|
$21,824,400
$60.0 P/Share
|
|
Nov 19
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,554
+38.66%
|
$183,324
$6.0 P/Share
|
|
Nov 13
2024
|
Kevin Robert Lind President and CEO |
SELL
Bona fide gift
|
Direct |
80,000
-18.03%
|
-
|
|
Nov 13
2024
|
Kevin Robert Lind President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,808
+2.81%
|
$38,424
$3.12 P/Share
|
|
Oct 15
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Direct |
16,667
-48.19%
|
$983,353
$59.03 P/Share
|
|
Oct 15
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+32.52%
|
$66,668
$4.35 P/Share
|
|
Sep 16
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Direct |
16,666
-14.76%
|
$533,312
$32.47 P/Share
|
|
Sep 16
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+32.52%
|
$66,664
$4.35 P/Share
|
|
Aug 12
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Direct |
16,667
-27.98%
|
$566,678
$34.79 P/Share
|
|
Aug 12
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+32.52%
|
$66,668
$4.35 P/Share
|
|
Aug 12
2024
|
Kevin Robert Lind President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
82,482
+8.14%
|
$247,446
$3.66 P/Share
|
|
Jun 25
2024
|
Randall Kaye Executive Vice President & CMO |
SELL
Open market or private sale
|
Indirect |
100
-100.0%
|
$2,000
$20.87 P/Share
|
|
Feb 08
2024
|
Brandi Roberts Executive VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,090
+50.0%
|
-
|
|
Feb 08
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
17,920
+50.0%
|
-
|
|
Jan 25
2024
|
Arena Pharmaceuticals Inc |
SELL
Open market or private sale
|
Direct |
3,978,540
-100.0%
|
$95,484,960
$24.25 P/Share
|
|
Jan 23
2024
|
Randall Kaye Executive Vice President & CMO |
BUY
Open market or private purchase
|
Indirect |
100
+50.0%
|
$2,400
$24.82 P/Share
|
|
Mar 16
2021
|
Arena Pharmaceuticals Inc |
BUY
Conversion of derivative security
|
Direct |
138,000
+3.35%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 176K shares |
|---|---|
| Grant, award, or other acquisition | 33K shares |
| Open market or private purchase | 100 shares |
| Open market or private sale | 4.03M shares |
|---|---|
| Bona fide gift | 80K shares |
| Disposition due to a tender of shares in a change of control transaction | 394K shares |